Characterizing the Metabolic Fate and Pharmacokinetics of the RyR2 Inhibitor ent-Verticilide
- 1Lipscomb University College of Pharmacy
Abstract
ent-Verticilide is a synthetic macrocyclic depsipeptide and ryanodine receptor 2 (RyR2) inhibitor with potential therapeutic applications in cardiac arrhythmias. This study characterized its in vitro metabolism and in vivo pharmacokinetics to better understand factors that may influence its disposition. Metabolic stability was evaluated in mouse, rat, dog, and human liver S9 fractions, followed by CYP reaction phenotyping in human liver microsomes and metabolite profiling in human and rat liver S9 fractions. Pharmacokinetics were evaluated in rats following intravenous and oral administration. ent-Verticilide underwent rapid, NADPH-dependent depletion across all species, with in vitro half-lives ranging from 2.1 to 5.3 min. CYP reaction phenotyping indicated that CYP3A was the predominant CYP subfamily involved in its metabolism. Eight putative metabolites were identified in human and rat liver S9, primarily resulting from hydroxylation, oxidation, and desaturation, with generally similar metabolite profiles between species. In rats, ent-verticilide exhibited a systemic clearance of 29.6 mL/min/kg, a steady-state volume of distribution of 4.86 L/kg, and a terminal half-life of 6.85 h following intravenous administration. Absolute oral bioavailability was 10.5%. Overall, these findings show that ent-verticilide undergoes extensive oxidative hepatic metabolism and provide an initial DMPK framework for its continued preclinical development.
Related
- Characterization of the Preclinical in Vitro and in Vivo Pharmacokinetic Properties of the Cyclic Oligomeric Depsipeptide Ryanodine Receptor 2 Inhibitor ent-Verticilide
- Longitudinal PET Imaging Reveals the Biological Fate, Pharmacokinetics, and Clearance of Zirconium-89-Labeled MXene Nanosheets In Vivo.
- Phase 1 Evaluation of the Pharmacokinetics of Sevasemten (EDG-5506) for Potential Food Effect and Drug-Drug Interaction With a CYP3A4 Moderate Inhibitor.
- Pharmacokinetics and Safety Evaluation of the Transglutaminase 2 Inhibitor Suvigletistat in Healthy Chinese, Japanese, and White/European Participants.
- Safety, Tolerability, and Pharmacokinetics of EGT710, a Novel Coronavirus Mpro Inhibitor, in Healthy Adults: A Randomized, Single- and Multiple-Dose Study.
BibTeX
@misc{do2026characterizing,
title = {{Characterizing the Metabolic Fate and Pharmacokinetics of the RyR2 Inhibitor ent-Verticilide}},
author = {T. Q. Do and R. D. Crouch and M. P. Thorpe and K. M. Johnson and J. Rumsey and J. N. Johnston and B. C. Knollmann and W. S. Akers},
howpublished = {bioRxiv},
year = {2026},
month = oct,
doi = {10.64898/2026.10.31.763093},
url = {https://www.biorxiv.org/content/10.64898/2026.10.31.763093v1},
note = {CC BY-NC-ND},
}
RIS
TY - UNPB
TI - Characterizing the Metabolic Fate and Pharmacokinetics of the RyR2 Inhibitor ent-Verticilide
AU - T. Q. Do
AU - R. D. Crouch
AU - M. P. Thorpe
AU - K. M. Johnson
AU - J. Rumsey
AU - J. N. Johnston
AU - B. C. Knollmann
AU - W. S. Akers
PY - 2026
DA - 2026/10/31
PB - bioRxiv
DO - 10.64898/2026.10.31.763093
UR - https://www.biorxiv.org/content/10.64898/2026.10.31.763093v1
AB - ent-Verticilide is a synthetic macrocyclic depsipeptide and ryanodine receptor 2 (RyR2) inhibitor with potential therapeutic applications in cardiac arrhythmias. This study characterized its in vitro metabolism and in vivo pharmacokinetics to better understand factors that may influence its disposition. Metabolic stability was evaluated in mouse, rat, dog, and human liver S9 fractions, followed by CYP reaction phenotyping in human liver microsomes and metabolite profiling in human and rat liver S9 fractions. Pharmacokinetics were evaluated in rats following intravenous and oral administration. ent-Verticilide underwent rapid, NADPH-dependent depletion across all species, with in vitro half-lives ranging from 2.1 to 5.3 min. CYP reaction phenotyping indicated that CYP3A was the predominant CYP subfamily involved in its metabolism. Eight putative metabolites were identified in human and rat liver S9, primarily resulting from hydroxylation, oxidation, and desaturation, with generally similar metabolite profiles between species. In rats, ent-verticilide exhibited a systemic clearance of 29.6 mL/min/kg, a steady-state volume of distribution of 4.86 L/kg, and a terminal half-life of 6.85 h following intravenous administration. Absolute oral bioavailability was 10.5%. Overall, these findings show that ent-verticilide undergoes extensive oxidative hepatic metabolism and provide an initial DMPK framework for its continued preclinical development.
ER -